FDA Advisory Committee Approval of First Biosimilar Leaves Questions Unanswered: Sandoz's Filgrastim Faces Naming and Court Hurdles. [electronic resource]
Producer: 20150323Description: 147 p. digitalISSN:- 1052-1372
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.